RG-6333

• Description:

  RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001) [1][2].

• Product Name Alternative:

  RO7443904

• UNSPSC:

  12352203

• Target:

  CD19; CD28

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Purity:

  98.05

• Smiles:

  [RG-6333]

• References & Citations:

  [1]Sam J, et al. CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy. Blood. 2024 May 23;143 (21) :2152-2165.|[2]Sam J, et al. RG6333 (CD19-CD28), a CD19-targeted affinity-optimized CD28 bispecific antibody, enhances and prolongs the anti-tumor activity of glofitamab (CD20-TCB) in preclinical models. Blood 140.Supplement 1 (2022) : 3142-3143.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  -80°C

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 1